ATE249462T1 - Neue kristalline form von n-(4-(2-(2-amino-4,7- dihydro-4-oxo-3h-pyrrolo(2,3-d)-pyrimidin-5- yl)ethyl)benzoyl)-l-glutaminsäure und verfahren für ihre herstellung - Google Patents

Neue kristalline form von n-(4-(2-(2-amino-4,7- dihydro-4-oxo-3h-pyrrolo(2,3-d)-pyrimidin-5- yl)ethyl)benzoyl)-l-glutaminsäure und verfahren für ihre herstellung

Info

Publication number
ATE249462T1
ATE249462T1 AT01906554T AT01906554T ATE249462T1 AT E249462 T1 ATE249462 T1 AT E249462T1 AT 01906554 T AT01906554 T AT 01906554T AT 01906554 T AT01906554 T AT 01906554T AT E249462 T1 ATE249462 T1 AT E249462T1
Authority
AT
Austria
Prior art keywords
pyrrolo
pyrimidine
dihydro
benzoyl
oxo
Prior art date
Application number
AT01906554T
Other languages
English (en)
Inventor
Erik Christopher Chelius
Susan Marie Reutzel-Edens
Sharon Van Den Berghe Snorek
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22679017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE249462(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE249462T1 publication Critical patent/ATE249462T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
AT01906554T 2000-02-25 2001-02-12 Neue kristalline form von n-(4-(2-(2-amino-4,7- dihydro-4-oxo-3h-pyrrolo(2,3-d)-pyrimidin-5- yl)ethyl)benzoyl)-l-glutaminsäure und verfahren für ihre herstellung ATE249462T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18496400P 2000-02-25 2000-02-25
PCT/US2001/001229 WO2001062760A2 (en) 2000-02-25 2001-02-12 A NOVEL CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR

Publications (1)

Publication Number Publication Date
ATE249462T1 true ATE249462T1 (de) 2003-09-15

Family

ID=22679017

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01906554T ATE249462T1 (de) 2000-02-25 2001-02-12 Neue kristalline form von n-(4-(2-(2-amino-4,7- dihydro-4-oxo-3h-pyrrolo(2,3-d)-pyrimidin-5- yl)ethyl)benzoyl)-l-glutaminsäure und verfahren für ihre herstellung

Country Status (36)

Country Link
US (1) US7138521B2 (de)
EP (1) EP1259513B1 (de)
JP (1) JP4846158B2 (de)
KR (1) KR100744917B1 (de)
CN (1) CN1183135C (de)
AR (1) AR029471A1 (de)
AT (1) ATE249462T1 (de)
AU (1) AU777047B2 (de)
BR (1) BR0108604A (de)
CA (1) CA2400155C (de)
CO (1) CO5261585A1 (de)
CZ (1) CZ303772B6 (de)
DE (1) DE60100750T2 (de)
DK (1) DK1259513T3 (de)
DZ (1) DZ3283A1 (de)
EA (1) EA004684B1 (de)
EG (1) EG24073A (de)
ES (1) ES2206403T3 (de)
HK (1) HK1051856A1 (de)
HR (1) HRP20020701B1 (de)
HU (1) HU229704B1 (de)
IL (2) IL150480A0 (de)
MX (1) MXPA02008242A (de)
MY (1) MY124784A (de)
NO (1) NO323422B1 (de)
NZ (1) NZ519796A (de)
PE (1) PE20011082A1 (de)
PL (1) PL208061B1 (de)
PT (1) PT1259513E (de)
SI (1) SI1259513T1 (de)
SK (1) SK287375B6 (de)
SV (1) SV2002000321A (de)
TW (1) TWI237024B (de)
UA (1) UA72791C2 (de)
WO (1) WO2001062760A2 (de)
ZA (1) ZA200205265B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100364993C (zh) * 2003-05-30 2008-01-30 江苏恒瑞医药股份有限公司 培美曲噻盐及其制备方法
CN100364994C (zh) * 2004-11-25 2008-01-30 重庆医药工业研究院有限责任公司 培美曲塞二钠的一种新晶型及其制备方法
JP2009514889A (ja) * 2005-11-04 2009-04-09 メルク エンド カムパニー インコーポレーテッド 癌を治療するためにｓａｈａ及びボルテゾミブを用いる方法
EP1942907A2 (de) * 2005-11-04 2008-07-16 Merck and Co., Inc. Verfahren zur verwendung von saha und erlotinib zur krebsbehandlung
JP2008543975A (ja) 2006-08-14 2008-12-04 シコール インコーポレイティド 高度に純粋なペメトレキセド二酸およびその調製方法
WO2008021411A2 (en) * 2006-08-14 2008-02-21 Sicor Inc. Processes for the preparation of lyophilized pharmaceutically acceptable salts of pemetrexed diacid
WO2008021385A2 (en) * 2006-08-14 2008-02-21 Sicor Inc. Processes for preparing intermediates of pemetrexed
ATE490257T1 (de) * 2006-08-14 2010-12-15 Sicor Inc Kristalline formen von pemetrexed-disäure und herstellungsverfahren dafür
CA2667348A1 (en) * 2006-11-03 2008-05-15 University Of Maryland, Baltimore Methods of using saha and bortezomib for treating multiple myeloma
BRPI0807939A2 (pt) * 2007-04-03 2014-07-01 Reddys Lab Ltd Dr Formas sólidas de pemetrexed
CN101417998B (zh) * 2007-10-24 2012-10-24 重庆医药工业研究院有限责任公司 一种培美曲塞盐的纯化方法
EP2072518A1 (de) 2007-12-23 2009-06-24 Sun Pharma Advanced Research Company Limited Stabile amorphe Form aus Pemextred Disodium
EP2334685A4 (de) * 2008-09-08 2011-10-26 Reddys Lab Ltd Dr Amorphes pemetrexed-dinatrium
WO2010030598A2 (en) * 2008-09-11 2010-03-18 Dr. Reddy's Laboratories Limited Pharmaceutical formulations comprising pemetrexed
CN101684121B (zh) 2008-09-22 2013-04-03 重庆医药工业研究院有限责任公司 培美曲塞二酸的新晶型及其制备方法
CN102050825B (zh) * 2009-11-05 2014-12-17 上海创诺制药有限公司 制备培美曲塞二钠2.5水结晶的方法
US9174991B2 (en) 2009-11-24 2015-11-03 Azad Pharmaceutical Ingredients Ag Crystalline form of pemetrexed disodium
CN102372719B (zh) * 2010-08-26 2013-10-30 齐鲁制药有限公司 培美曲塞二甲酯对甲苯磺酸盐晶型及其制备方法
KR101069128B1 (ko) * 2011-03-10 2011-09-30 건일제약 주식회사 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법
US9051322B2 (en) 2011-03-23 2015-06-09 Scinopharm Taiwan, Ltd. Process for the production of a pemetrexed salt
JP5826371B2 (ja) * 2011-03-25 2015-12-02 サイノファーム タイワン リミテッド ペメトレキセド塩の製造方法
ITRM20120398A1 (it) 2012-08-08 2014-02-09 Berlin Chemie Ag Procedimento di sintesi pemetrexed e suo sale di lisina.
CN102911176B (zh) * 2012-10-10 2015-07-22 德州德药制药有限公司 一种培美曲塞二钠的制备方法
WO2014060959A1 (en) * 2012-10-17 2014-04-24 Shilpa Medicare Limited Crystalline pemetrexed dipotassium process
WO2014122460A2 (en) 2013-02-06 2014-08-14 Cipla House Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes
EP3308770A1 (de) 2013-04-12 2018-04-18 Actavis Group PTC EHF Pemetrexed-formulierung
KR101485243B1 (ko) 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제
JP6094388B2 (ja) * 2013-06-07 2017-03-15 ニプロ株式会社 ペメトレキセドを含む注射用組成物
ES2657944T3 (es) 2013-06-14 2018-03-07 Synthon B.V. Sal estable de arginina de pemetrexed y composiciones que la comprenden
JP2016527227A (ja) 2013-07-16 2016-09-08 ドクター レディズ ラボラトリーズ リミテッド ペメトレキセドトロメタミン塩の新規な結晶形
WO2015050230A1 (ja) 2013-10-03 2015-04-09 富士フイルム株式会社 注射液製剤及びその製造方法
NZ630292A (en) * 2013-11-25 2015-02-27 Shilpa Medicare Ltd Process for crystalline pemetrexed dipotassium salt
NZ630299A (en) 2014-06-30 2014-11-28 Shilpa Medicare Ltd Pemetrexed dipotassium formulations
WO2016068796A1 (en) * 2014-10-30 2016-05-06 Scinopharm Taiwan, Ltd. Crystalline forms of pemetrexed diacid and manufacturing processes therefor
CN105566328B (zh) * 2014-11-06 2018-04-24 博瑞生物医药（苏州）股份有限公司 培美曲塞二酸多晶型的制备方法
PL3804686T3 (pl) * 2017-10-10 2023-12-11 Sun Pharmaceutical Industries Ltd Dożylna infuzyjna postać dawkowania dla pemetreksedu

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO169490C (no) * 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
KR0162654B1 (ko) 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
US5416211A (en) 1992-09-25 1995-05-16 Eli Lilly And Company Process for preparing 5-substituted pyrrolo-[2,3-d]pyrimidines
WO1998008382A1 (en) * 1996-08-30 1998-03-05 Eli Lilly And Company Nonclassical pyrrolo[2,3-d]pyrimidine antifolates
ZA987550B (en) * 1997-09-26 2000-02-21 Lilly Co Eli Processes and intermediates useful to make antifolates.
PL196216B1 (pl) * 1997-09-26 2007-12-31 Lilly Co Eli Sposób wytwarzania 5-podstawionych związków pirolo[2,3-d]pirymidyny
WO2001014379A2 (en) * 1999-08-23 2001-03-01 Eli Lilly And Company A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor

Also Published As

Publication number Publication date
DZ3283A1 (fr) 2001-08-30
AR029471A1 (es) 2003-07-02
KR20020075449A (ko) 2002-10-04
US7138521B2 (en) 2006-11-21
HRP20020701B1 (en) 2011-02-28
IL150480A (en) 2007-12-03
CZ303772B6 (cs) 2013-05-02
HUP0204232A3 (en) 2006-01-30
DE60100750T2 (de) 2004-07-29
UA72791C2 (uk) 2005-04-15
CA2400155C (en) 2009-09-15
US20030216416A1 (en) 2003-11-20
EG24073A (en) 2008-05-11
CZ20022875A3 (cs) 2003-02-12
DE60100750D1 (de) 2003-10-16
EP1259513A2 (de) 2002-11-27
WO2001062760A2 (en) 2001-08-30
SI1259513T1 (en) 2003-12-31
SK287375B6 (sk) 2010-08-09
MXPA02008242A (es) 2002-11-29
EA200200905A1 (ru) 2003-02-27
HU229704B1 (en) 2014-05-28
CN1183135C (zh) 2005-01-05
HUP0204232A2 (hu) 2003-04-28
CO5261585A1 (es) 2003-03-31
CN1406238A (zh) 2003-03-26
BR0108604A (pt) 2002-11-19
PE20011082A1 (es) 2001-10-22
PT1259513E (pt) 2004-02-27
MY124784A (en) 2006-07-31
NZ519796A (en) 2003-01-31
HK1051856A1 (en) 2003-08-22
PL356423A1 (en) 2004-06-28
JP4846158B2 (ja) 2011-12-28
TWI237024B (en) 2005-08-01
ES2206403T3 (es) 2004-05-16
DK1259513T3 (da) 2004-01-12
KR100744917B1 (ko) 2007-08-01
JP2003530321A (ja) 2003-10-14
NO323422B1 (no) 2007-04-30
NO20023974D0 (no) 2002-08-21
AU3445101A (en) 2001-09-03
IL150480A0 (en) 2002-12-01
AU777047B2 (en) 2004-09-30
WO2001062760A3 (en) 2001-12-06
SV2002000321A (es) 2002-07-16
ZA200205265B (en) 2003-11-11
CA2400155A1 (en) 2001-08-30
EP1259513B1 (de) 2003-09-10
PL208061B1 (pl) 2011-03-31
SK11862002A3 (sk) 2003-01-09
NO20023974L (no) 2002-08-21
HRP20020701A2 (en) 2003-12-31
EA004684B1 (ru) 2004-06-24

Similar Documents

Publication Publication Date Title
ATE249462T1 (de) Neue kristalline form von n-(4-(2-(2-amino-4,7- dihydro-4-oxo-3h-pyrrolo(2,3-d)-pyrimidin-5- yl)ethyl)benzoyl)-l-glutaminsäure und verfahren für ihre herstellung
RS52142B (sr) 8-[3-amino-piperidin-1-il]-ksantini, njihovo dobijanje i njihova primena kao farmaceutskih kompozicija
CL2010000204A1 (es) Compuestos intermediarios derivados de 4 amino-3-metoxibenzamida; compuesto intermediario n-{4-[4-(ciclopropilmetil)piperazin-1-il]ciclohexil}acetamida; compuesto intermediario 2-cloro-7-etil-7,8-dihidro-5-metil-8-(1-metiletil)-6(5h)-pteridinona, útiles en la preparación de dihidropteridinonas sustituidas (divisional sol. 2077-05).
DE60128457D1 (de) 1,5-DISUBSTITUIERTE 3,4-DIHYDRO-1H-4,5-DöPYRIMIDIN-2-ON-VERBINDUNGEN UND IHRE VERWENDUNG IN DER BEHANDLUNG VON DURCH CSBP/P38 KINASE BEEINFLUSSTEN KRANKHEITEN
ATE396719T1 (de) Verwendung von (z)-2-cyano-3-hydroxy-but-2- ensäure-(4'-trifluoromethylphenyl)-amid zur behandlung der multiplen sklerose
DZ3156A1 (fr) Nouvelle forme polymorphe du sel d'acide 5-Ä4-Ä2-(n-methyl-n-(2-pyridyl)amino)ethoxyÜbenzylÜthiazolidine-2,4-dione, maleique.
SK1452000A3 (en) Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists
ATE218335T1 (de) Salze der ketosäuren und amine sowie ihre verwendung zur herstellung von medikamenten
DE69813565D1 (de) Substituierte 3,3-diamino-2-propennitrile, ihre herstellung und verwendung
DE60239842D1 (de) Verfahren zur Herstellung von 10,11-dihydro-10-oxo-5h-dibenzoÄb,fÜazepin-5-carboxamid
TR28873A (tr) N-sübstitüe edilmis, N,N'-kaynasik heterosiklik benzoik asit üretmeye mahsus yöntem.
DE60330199D1 (de) Verfahren zur Herstellung von n1-(2-pyridyl)-1,2-Propandiaminsulfamidsäure und ihre Verwendung zur Herstellung von biologisch aktiven Piperazinen
RU94003397A (ru) Производные 2-/4-(4-азолилбутил)-1-пиперазинил/-пиримидина, способ их получения и фармацевтическая композиция на их основе
DE60213763D1 (de) Pyrimidine und verfahren zu deren herstellung
WO2001010861A3 (de) Substituierte heterocyclyl-2h-chromene
NO20043988L (no) Fremgangsmate for fremstilling av chirale 1,4-substituerte piperaziner
DK1075473T3 (da) Fremgangsmåde til fremstilling af 1,3-disubstituerede-4-oxocykliske urinstoffer
ITMI20002186A0 (it) Processo per la produzione dell'acido tiottico racemo
ATE300531T1 (de) Isonipecotamide zur behandlung von integrin vermittelten störungen
DE69800092T2 (de) Substituierte 4-(6-fluor-[1H]-indol-3-yl)1,2,3,6-Tetrahydropyridin-Derivate für die Behandlung von ZNS-Störungen
WO2003045917A3 (en) Ccr-3 receptor antagonists vii
WO2003004464A8 (de) Heterozyklische amidderivate und deren verwendung als schädlingsbekämpfungsmittel
ATE218558T1 (de) 4-(1-piperazinyl)benzosäurederivate, verfahren zu ihrer herstellung und ihre therapeutischen verwendungen
WO2003014094A3 (de) Heterocyclylarylsulfonamide
WO2001010849A3 (de) Substituierte arylalkylamino-1,3,5-triazine als herbizide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1259513

Country of ref document: EP